Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Oncoimmunology|October 6, 2018
Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effectsLien De Beck, Sarah Melhaoui, Kim De Veirman, et al.
Oncotarget|November 12, 2015
The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cellsJinheng Wang, Kim De Veirman, Nathan De Beule, et al.
Frontiers in Immunology|October 28, 2022
The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancersRong Fan, Nathan De Beule, Anke Maes, et al.
Oncotarget|June 4, 2015
Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatmentCharlotte Fristedt Duvefelt, Susanne Lub, Prasoon Agarwal, et al.
Cancers|November 8, 2019
AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple MyelomaSiyang Yan, Niels Vandewalle, Nathan De Beule, et al.
Oncotarget|May 17, 2014
The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myelomaKen Maes, Eva De Smedt, Miguel Lemaire, et al.
Blood Advances|May 3, 2021
G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell deathEva De Smedt, Julie Devin, Catharina Muylaert, et al.
Blood Cancer Journal|November 20, 2019
Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphomaAnke Maes, Ken Maes, Philip Vlummens, et al.
Oncotarget|April 30, 2016
The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialLiesbeth Bieghs, Hans E Johnsen, Ken Maes, et al.
Oncotarget|February 12, 2015
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myelomaKen Maes, Eva De Smedt, Alboukadel Kassambara, et al.
Pageof 5